Supercharged immune cells unleashed in Multi-Target attack on blood cancers
NCT ID NCT03125577
Summary
This trial is testing a new combination of engineered immune cell therapies for people with hard-to-treat B-cell cancers. It aims to improve treatment and prevent cancer from coming back by using cells that target up to seven different markers on cancer cells at once. The study will first check the safety of this approach and then see how well it works in patients whose cancer has returned or not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
RECRUITINGKunming, Yunnan, 650000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.